[VIRTUAL] Experimental new imaging in brain metastasis and translation to patients

[VIRTUAL] Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)

[VIRTUAL] MGMT promoter status in IDH1/2 mutant anaplastic astrocytoma patients assessed by DNA methylation profiling and qMS-PCR: a report from the EORTC Brain Tumor Group

[VIRTUAL] A Phase 0/1 'Trigger' Trial of Ribociclib Plus Everolimus in Recurrent High-Grade Glioma

[VIRTUAL] Short-term fasting in glioma patients - Analysis of diet diaries and metabolic parameters of the ERGO2 trial

[VIRTUAL] First in human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) clinical trial in patients with recurrent high-grade glioma shows immunologic changes in injected tumors

[VIRTUAL] BORTEM-17: A Phase IB/II Single-Arm, Control Non-Randomized, Multicentre, Open Label Clinical Trial for Recurrent Glioblastoma with unmethylated MGMT promoter (NCT03643549)

[VIRTUAL] Quality of life of patients with newly diagnosed glioblastoma during TTFields therapy in routine clinical care: first results of the TIGER study

[VIRTUAL] Phase 1 with dose expansion/phase2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma

[VIRTUAL] INDIGO: A global, randomized, double-blind, phase 3 study of vorasidenib (AG-881) versus placebo in patients with residual/recurrent grade II isocitrate dehydrogenase 1/2-mutant (mIDH1/2) glioma

[VIRTUAL] Radiomics features in prediction of pseudo-progression and response to hypofractionated stereotactic radiotherapy and anti-PDL1 Durvalumab combination in recurrent glioblastoma from STERIMGLI phase I trial.